There are currently 58 active clinical trials seeking participants for Atopic Dermatitis research studies. The states with the highest number of trials for Atopic Dermatitis participants are California, Florida, Texas and Ontario.
Natural History and Genetics of Food Allergy and Related Conditions
NCT02504853
Recruiting
Background: - About 15 million Americans have a food allergy. Because there are no cures or effective prevention or treatment for food allergies, researchers want to learn more about them. Objective: - To learn more about the causes and effects of food allergy and related conditions. Eligibility: People ages 2 99 who have food allergy and/or a related genetic or other condition Their relatives Healthy relatives and volunteers Design: Participants will have at least 3 visits over 1 2 years... Read More
Gender:
All
Ages:
Between 1 day and 99 years
Trial Updated:
06/07/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Food Allergy, Loeys-Dietz Syndrome, Atopic Dermatitis, Eosinophilic Esophagitis
Register for Updates
Cardamom and Topical Roseomonas in Atopic Dermatitis
NCT06096857
Recruiting
Background: Atopic dermatitis (AD), also called eczema, is a chronic skin condition. AD can make skin dry and itchy, and sometimes it can lead to serious health problems, such as asthma, food allergies, eye infections, and sleep problems. No cure exists for AD. Researchers know that people with AD have different kinds of harmless bacteria on their skin than do people without AD. They want to see if adding a harmless bacteria (Roseomonas mucosa) to the skin can help people with AD. Objective:... Read More
Gender:
All
Ages:
Between 2 years and 100 years
Trial Updated:
06/06/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Atopic Dermatitis, Eczema
Register for Updates
A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe AD
NCT06224192
Recruiting
The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneous using devices for injection at home.
Gender:
All
Ages:
Between 12 years and 100 years
Trial Updated:
06/05/2024
Locations: Kern Research Inc, Bakersfield, California +29 locations
Conditions: Atopic Dermatitis
Register for Updates
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
NCT00605878
Recruiting
This study will examine microbes (e.g., bacteria, fungi, viruses) that live on human skin and how microbes contribute to health and disease. It will analyze healthy human skin and how the these microorganisms might change in patients with atopic dermatitis (AD), a skin condition also known as eczema. Healthy volunteers, as well as patients with moderate to severe eczema (AD), between 2 and 40 years of age may be eligible for this study. We also wish to enroll children and adults aged 2-40 who... Read More
Gender:
All
Ages:
Between 2 years and 100 years
Trial Updated:
06/05/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Atopic Dermatitis, Eczema, Ichthyosis Vulgaris
Register for Updates
Study of Skin Microbiome in AD and PS Patients
NCT04170244
Recruiting
Everybody's skin has bacteria that normally lives on it. Previous research has shown that people with eczema (or atopic dermatitis [AD]) have much higher concentrations of a certain bacteria (S. aureus), especially when their disease is active but little is known about the role that this bacteria plays in psoriasis (i.e. disease severity, biomarkers and skin barrier function). The overarching purpose of this longitudinal study is to understand how the abundance of skin S. aureus (and several com... Read More
Gender:
All
Ages:
13 years and above
Trial Updated:
06/03/2024
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Atopic Dermatitis, Psoriasis
Register for Updates
A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis
NCT05923099
Recruiting
The purpose of this trial is to test different doses of the trial medicine (LEO 138559) at treating moderate to severe atopic dermatitis in adults. There will be 4 different doses, that will also be compared to a placebo (a dummy medicine that doesn't contain the active ingredient of LEO 138559). Each participant will be randomly assigned to one of the 4 doses of LEO 138559 or placebo. In all arms, injections of placebo may be used to mask the different doses. The trial will last up to 36 weeks... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/23/2024
Locations: LEO Investigational Site, Fountain Valley, California +72 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
NCT06436183
Recruiting
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/22/2024
Locations: Medical Dermatology Specialists, PC/US Dermatology Partners, Phoenix, Arizona +27 locations
Conditions: Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
Register for Updates
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
NCT05995964
Recruiting
The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction. This study is seeking participants who: are 18 years of age or more. Were confirmed to have AD at least 6 months ago. Are not having an effective treatment result from medicines that are applied on skin for AD. Are considered by their doctors to have moderate to severe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: Allervie Clinical Research, Birmingham, Alabama +47 locations
Conditions: Atopic Dermatitis
Register for Updates
A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
NCT05277571
Recruiting
The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy study participants and after repeat intravenous dosing in study participants with atopic dermatitis. Efficacy will be assessed following repeat intravenous dosing versus placebo in study participants with atopic dermatitis.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/08/2024
Locations: Up0110 117, North Little Rock, Arkansas +23 locations
Conditions: Atopic Dermatitis
Register for Updates
Seal, Stopping Eczema and Allergy Study
NCT03742414
Recruiting
This is a randomized, controlled trial designed for children who are have already developed atopic dermatitis (AD or eczema) by 12 weeks of age. The aim is to compare the effect of proactive sequential skin care, including the twice-daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone propionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
Gender:
All
Ages:
Between 1 week and 12 weeks
Trial Updated:
05/08/2024
Locations: Sean N. Parker Center for Allergy & Asthma Research at Stanford University, Palo Alto, California +4 locations
Conditions: Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis
Register for Updates
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
NCT05635266
Recruiting
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
05/03/2024
Locations: Sanguine Biosciences, Waltham, Massachusetts
Conditions: Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Register for Updates
Study of TDM-180935 in Atopic Dermatitis Patients
NCT06363461
Recruiting
Randomized, Vehicle-controlled, Parallel Group Study of TDM-180935 in Atopic Dermatitis Patients
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: Site 5, Rolling Meadows, Illinois +6 locations
Conditions: Atopic Dermatitis
Register for Updates